累计融资1.92亿，AMT Medical如何让患者告别“开胸之痛”？

Core Insights - AMT Medical has developed the ELANA seamless heart bypass technology, allowing surgeries without chest opening, thus reducing patient trauma and recovery time [1][4][16] Industry Overview - Cardiovascular diseases (CVDs) remain a leading cause of death globally, with approximately 18.5 million deaths in 2023, projected to rise to 24 million by 2030 [2] - Traditional coronary artery bypass grafting (CABG) surgeries face significant challenges, including chest trauma, recovery difficulties, and high medical costs [2][3] Technology Advantages - The ELANA system utilizes laser-assisted vascular connections and specialized clips, enabling surgeries without sutures and heart-lung machines, thus maintaining blood circulation during procedures [4][5][7] - The system significantly reduces stroke risk from 3%-5% in traditional surgeries to less than 1% with ELANA, and lowers anastomosis leak rates from 8%-12% to below 2% [9][10] Market Potential - The global minimally invasive surgery market is projected to grow from $62 billion in 2023 to $130 billion by 2030, with cardiovascular devices accounting for over 30% of this market [3] - AMT's technology is adaptable for various surgical methods and has potential applications in peripheral vascular bypass and heart valve repair, expanding its market reach [10][15] Financial Backing - AMT has raised a total of €24.5 million (approximately $26 million) in funding, including a recent €22 million Series B round to accelerate CE certification and clinical trials in the U.S. [11][12][13] Future Plans - The company aims to achieve CE certification by 2026 and initiate FDA approval processes in 2027, targeting to reduce surgical costs by an additional 30% and benefit one million patients annually [15][16]